We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > uveitis

News List

Sales of long-acting immunosuppressants for non-infectious uveitis to touch $357 mn by 2029: GlobalData expresspharma
July 06, 2021
Corticosteroids are typically the first line of therapy for most patients with uveitis as these drugs are very effective and have anti-inflammatory effects.
EyePoint Announces Positive Topline Follow-up Data for Study of YUTIQ americanpharmaceuticalreview
March 04, 2020
EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second Phase 3 trial of YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert ...
Mycophenolate Mofetil Does Not Top MTX in Noninfectious Uveitis drugs
September 12, 2019
For adults with noninfectious uveitis, mycophenolate mofetil is not associated with superior control of inflammation compared with methotrexate...
Final NHS nod for Allergan’s Ozurdex, AbbVie’s Humira in uveitis pharmatimes
July 28, 2017
Cost regulators for NHS treatments in England and Wales have deemed AbbVie’s Humira and Allergan’s Ozurdex clinically and cost effective for treating adults with...